Drug Oncology

Ibrance

Payments companies reported to CMS as associated with Ibrance. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2.7Massociated payments (2023-2025)

8,392clinicians with associated payments

7companies reporting

By year

2023 $823K

2024 $984K

2025 $891K

Payments reported as associated with Ibrance, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Hematology & Oncology $1.0M

Medical Oncology $804K

Family $157K

Nurse Practitioner $104K

Internal Medicine $72K

Diagnostic Radiology $60K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Ibrance

These are the largest totals companies reported as associated with Ibrance. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Anne Odea	Westwood, KS	Medical Oncology	$266,236.70
Adam Brufsky	Pittsburgh, PA		$150,319.64
Linnea Chap	Beverly Hills, CA	Hematology & Oncology	$109,320.20
Neil Iyengar	New York, NY	Hematology & Oncology	$105,116.88
Richard Finn	Santa Monica, CA	Hematology & Oncology	$99,121.14
Sramila Aithal	Bensalem, PA	Medical Oncology	$93,453.25
Reshma Mahtani	Plantation, FL	Medical Oncology	$80,999.72
Priya Rudolph	Athens, GA	Hematology & Oncology	$79,280.56
Hope Rugo	San Francisco, CA	Hematology (Internal Medicine)	$51,962.50
Ruta Rao	Chicago, IL	Medical Oncology	$41,205.78

Prescribed Ibrance?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.